Updated Outcomes of Sacituzumab Govitecan in Resistant Advanced Urothelial Carcinoma
1. The objective response rate was 28% with a complete response of 5.6% and a partial response of 23%. 2. ...
Tag: Sacituzumab govitecan
Sacituzumab govitecan shows survival benefit in endocrine-resistant hormone-positive metastatic breast cancer
1. Median overall survival increased by 3.2 months in the sacituzumab govitecan group compared to chemotherapy. 2. One fatal treatment-related ...
Sacituzumab govitecan may be an effective treatment for heavily pre-treated HR+/HER2- metastatic breast cancer.
1. Median progression-free survival was longer in the SG group than in the chemotherapy group. 2. Median overall survival was ...
#VisualAbstract: Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...
Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...